Executive Director, People Experience Partnership and G&A HRBP
$250.2k/y-$375.3k/y
Apellis Pharmaceuticalsa day ago
Highlight
HybridFull-timeExecutive
Summary
Apellis Pharmaceuticals is seeking an Executive Director, People Experience Partnership and G&A HRBP to lead their People Experience Partnership model in Waltham, MA. The role focuses on consolidating HR Business Partnering, People Relations, and below-SLT HR support into a scalable organization.
About the Role
As the Executive Director, you will serve as the senior HR Business Partner for G&A functions, providing leadership oversight and ensuring strategic HR partnership, execution excellence, and governance across HRBP and People Experience delivery. You will collaborate with HR COEs and embedded HR partners to strengthen leadership trust and support Apellis' growth.
About You
Required:
- Bachelor's degree required; advanced degree in HR, Business, Law, Organizational Development, or related field preferred.
- 15+ years of progressive HR experience, including senior-level HRBP leadership.
- Demonstrated success leading HR organizations through scale, transformation, or operating-model redesign.
- Experience partnering with executive-level leaders in G&A and enterprise functions.
- Prior people-leadership experience managing HRBPs, HR Generalists, or People Relations teams.
Preferred:
- Enterprise HR leadership and strategic judgment.
- Executive coaching and influence.
- Organizational design and governance.
- Strong operational discipline and execution focus.
- Ability to balance strategy with hands-on leadership.
- Trusted advisor with credibility across the business.
Benefits
- Comprehensive benefits package including a 401(k) plan with company match.
- Inclusive family building benefits.
- Flexible time off, summer and winter shutdowns.
- Paid family leave, disability and life insurance.
Apellis Pharmaceuticals
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
Waltham, MA